Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objective of the trial is to evaluate the effects of ATX-MS-1467 administered intradermally, titrated to a dose of 800 μg every 2 weeks (biweekly), for a total period of 20 weeks on 1.5T MRI parameters compared to a Baseline Control Period off treatment in subjects with relapsing MS.
Inclusion criteria
- Relapsing Multiple Sclerosis